LipidBrick®

LipidBrick® is a novel range of proprietary cationic lipids dedicated to the formulation of LNPs for the development of mRNA-based vaccines and therapeutics.

Amount of Reagent
Item No.: 
101000232
Availability: 

*Custom/bulk order quotes are provided within 72 hours of request.

LipidBrick® is a unique library composed of innovative proprietary imidazolium-based cationic lipids dedicated to the formulation of lipid nanoparticles (LNPs). These active lipids safeguard mRNA molecules and enhance the transfection ability of LNPs. Each LipidBrick® lipid is permanently charged; therefore, unlike ionizable lipids, it confers an overall positive charge to LNPs, which induces extra-hepatic tropism. In addition, delivery efficacy and biodistribution can be fine-tuned by screening the LipidBrick® library to select the most suitable LipidBrick® lipid for each specific application therapeutic need.

Key Benefits:

  • Efficient: Modulate LNP properties to adapt biodistribution to therapeutic goals.
  • Secure: Unique structure protected by an independent patent held by Polyplus (now part of Sartorius).
  • Time-Saving: In vitro and in vivo proof of concept studies have been successfully performed.
  • Flexible: Versatile library for selecting the best LipidBrick® for each application.

Applications

  • Application
    Active cationic lipids for LNP formulation

Biological Information

  • Molecule delivered
    mRNA

Chemical Information

  • IUPAC/Chemical Name
    3-butyl-1-(2,6-dimethyl-14-octadecyldotriacontan-9-yl)-1H-imidazol-3-ium chloride.
  • Linear Formula
    C59H117ClN2

Compliance Information

  • Product Documentation
    • Protocol 
    • Certificate of Analysis 
    • Master Safety Data Sheet

General Specifications

  • Amount of Reagent
    LipidBrick® IM21.7c 50 mg

Storage Conditions

  • Storage Conditions
    -20 °C ± 5 °C

Weight

  • Molecular Weight (kDa)
    890.03 (g/mol)
´